ACCESS Newswire

A New Shade of Comfort: LiberNovo Omni Debuts New Moss Green Design

Share

HONG KONG, HK / ACCESS Newswire / January 6, 2026 / LiberNovo

The pioneer of dynamic ergonomic seating today announced the upcoming Moss Green variant of its flagship chair, the LiberNovo Omni , launching in Europe on January 17, 2026 (CET) . Building on the success of Midnight Black and Space Grey, Moss Green introduces a nature-inspired palette paired with a softer, upgraded fabric designed for long-hour comfort.

As hybrid work becomes the norm across Europe, professionals increasingly seek seating that integrates seamlessly into home environments while supporting extended periods of task switching. Moss Green offers a warm, understated aesthetic that blends naturally into modern workspaces. The new colorway retains the LiberNovo Omni's full Dynamic Support system, providing adaptive support whether users are deeply focused, shifting between tasks, or relaxing after long sessions.

A Calming Revival of Nature, Designed for Modern Work

Inspired by forest moss, the Moss Green tone blends deep green with a gentle warmth: grounded, understated, and quietly vibrant. The hue echoes biophilic design principles, bringing the emotional comfort of nature into everyday workflows.

Soft, balanced, and non-intrusive, Moss Green pairs beautifully with the LiberNovo Omni 's sculpted surface textures. Whether placed in a minimalist home office or a contemporary workspace, it subtly elevates the environment with a sense of composure and vitality, helping users restore equilibrium during long hours at a desk.

A Touch Upgrade: Wool-Like Softness, Re-Engineered for Daily Use

The Moss Green edition debuts a material refinement for the Omni: a short-pile velvet surface that feels soft and delicate while remaining breathable and skin-friendly. The texture introduces a gentle visual flow and a touch of quiet luxury to the chair's overall presence.

A specialized dyeing process preserves Moss Green 's purity and softness while resisting fading under daily use. The fabric exceeds industry durability benchmarks:

  • Abrasion resistance: Tested beyond 50,000 wear cycles

  • Pilling resistance: Grade 4 after 5,000 cycles

  • Color fastness (dry): Grade 4

  • Color fastness (wet): Grade 3-4

Maintaining the 45 cm and 48 cm seat depths preferred across European markets, the updated material delivers both tactile comfort and dependable longevity.

"We pushed deeper into the natural character of blended fibers to create a soft touch that grounds the user. It's effortless comfort that feels familiar and refined."

LiberNovo Omni's Core Features

The Moss Green edition retains the LiberNovo Omni's full Dynamic Support system, delivering real-time, full-body support for long-hour work:

  • Dynamic Support System: Responds instantly to posture changes

  • Bionic FlexFit Backrest: 16 pivot points and 8 adaptive panels for full-back alignment

  • Four Recline Modes: 105°, 120°, 135°, and 160°

  • OmniStretch: Deep spinal decompression designed to relieve pressure

LiberNovo Founder & CEO Alex Yan shares:

"Moss Green bridges innovation with introspection. In a world that rarely slows down, it grounds the user, supporting not just better posture, but better presence. It reflects our ongoing effort to address the challenges of long-hour sitting with design that puts people first."

Following the momentum of LiberNovo 's year-end campaigns, this European launch marks an important milestone in the company's 2026 expansion, uniting emotional well-being with intelligent ergonomic engineering.

Launch Exclusives

The official launch across Europe opens on January 17, featuring limited-time new-launch early-bird pricing , set below other color models. The LiberNovo Omni Moss Green Basic Bundle is available starting at €995 (MSRP €1,437), with additional bundles and accessories offered at discounted launch pricing.

The first 500 EU orders over €900 will receive an exclusive three-piece gift set, including a silk eye mask, eco tote bag, and footrest cushion.

Customers can sign up for early access notifications, pricing updates, and availability alerts.

Users can explore fabric swatches, visualize setups via the interactive configurator, and subscribe for updates at: www.libernovo.com

Join the natural-workspace movement.
Sit smart. Live freely.

Contact Information
Cassie Kuang
Integrated Marketing of LiberNovo
pr@libernovo.com

SOURCE: LiberNovo



View the original press release on ACCESS Newswire

LiberNovo

Subscribe to releases from ACCESS Newswire

Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from ACCESS Newswire

Datavault AI Announces Target to Expand its AI Driven Data Monetization Network to Over 100 Cities Across the Contiguous United States, Starting in the Second Half of 2026 with Corresponding 2027 Revenue Target12.1.2026 14:05:00 CET | Press Release

Datavault AI expects to have a fully operational network with over 100 nodes across 33 cities nationwide, generating revenue in the second half of 2026. Target revenue for this project is $400 to $500 million, thereby supporting the $200 million revenue guidance for 2026. With the full deployment of Datavault AI's nodes across 100+ cities throughout the United States, the 2027 revenue target is $2.0 to $3.0 billion for 2027. New York and Philadelphia edge network activation positions Datavault AI to potentially capture a significant share of the insurance and financial sectors, the healthcare industry, and enterprise opportunities. PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / January 12, 2026 / Datavault AI Inc. (Nasdaq:DVLT), a leader in AI-driven data valuation, monetization, credentialing, and digital engagement technologies, today highlighted the strategic importance of its New York and Philadelphia edge network deployment with Available Infrastructure's SanQtum AI platform. This

OBI Pharma and TegMine Therapeutics Sign Exclusive Global License Agreement for Glycan-Targeting ADC12.1.2026 13:00:00 CET | Press Release

Successful Delivery of Commissioned ADC Candidate to Advance the Collaboration Between OBI and TegMine TAIPEI, TW / ACCESS Newswire / January 12, 2026 / OBI Pharma (4174.TWO) announced that it has entered into a commercial license agreement with TegMine Therapeutics, Inc. (TegMine), a San Francisco-based biopharma focused on developing antibodies targeting cancer-associated glycans and glycoproteins, for a glycan-targeting ADC. Under the terms of the agreement, OBI is eligible to receive an upfront payment as well as development and commercial milestones. Following product launch, OBI will also receive royalties based on a tiered percentage of annual net sales. While the detailed financial terms are not disclosed in accordance with the confidentiality provisions, the overall deal economics are broadly comparable to those of recent similar licensing transactions in the market. TegMine will obtain the exclusive global rights to develop and commercialize the ADC under the license agreemen

Datavault AI Celebrates Successful Completion of Dream Bowl XIV, Pioneering Blockchain Innovation in Sports Entertainment12.1.2026 12:00:00 CET | Press Release

On January 10, 2026, a few dozen of NFL Alumni Greats (click here for a list of participating athletes) live-autographed 100 Footballs (click here to view the autographed NFL Alumni Footballs) and 500 Jerseys (click here to view the autographed NFL Alumni Jerseys); Starting on February 1, 2026, these special, one-time, live-autographed memorabilia items are to be given away by lottery to eligible holders of Dream Bowl Meme Coin I tokens and, following their distribution date (currently set for February 21, 2026), Dream Bowl Meme Coin II tokens and will be tradable on the upcoming International NIL Exchange; $25,000 E-Sports Scholarships Raised by Sponsors were Given to Dream Bowl Madden and Team E-Sports Champions; and 70 Student Star Athletes Showcased their Talent to USFL, NFL and European League Scouts (click here to view the Special Dream Bowl XIV Participants' Jerseys). PHILADELPHIA, PENNSYLVANIA / ACCESS Newswire / January 12, 2026 / Datavault AI Inc. (NASDAQ:DVLT) ("Datavault AI

Charlie's Holdings (OTCQB:CHUC) Signs Agreement with IKE Tech to Commercialize Transformational Age-Gated Vapes that Will Address FDA Concerns Related to Youth Access12.1.2026 12:00:00 CET | Press Release

SBX Product Line Will Feature First-Ever AI-Powered Blockchain-Based Age-Gating System for Vape Products IKE's patented biometric BLE Bluetooth chip and blockchain-based app will enable Charlie's to ensure that underage individuals will not be able to activate or utilize the Company's age-gated products. The IKE Licensing Agreement provides CHUC with a first mover advantage in youth access prevention (one of the FDA's top priorities) and a three-year exclusivity period for age-gated nicotine analogue products. Charlie's will test market the IKE age-gating system this spring with the Company's popular SBX nicotine analogue product line; simultaneously, Charlie's intends to incorporate the revolutionary technology into its PACHA branded Electronic Nicotine Delivery Systems (ENDS). COSTA MESA, CA / ACCESS Newswire / January 12, 2026 / Charlie's Holdings, Inc. (OTCQB:CHUC) ("Charlie's" or the "Company"), an industry leader in the premium vapor products space, today reported that the Compan

PromiCell, Inc. presents during JP Morgan's 2026 Healthcare Conference9.1.2026 18:35:00 CET | Press Release

MIAMI, FL / ACCESS Newswire / January 9, 2026 / PromiCell, Inc. (the "Company"), a clinical-stage cellular immunotherapy company uniquely positioned to advance potentially curative cell therapies for cancer patients, today announced that the Company's Chief Medical Officer, John Lee, MD, Ph.D., will present interim results of the Company's lead asset PRO CAR - 201A, a STEAP1 directed CAR T cell that is currently in the clinic as a first-in-human phase 1 trial for the treatment of metastatic castration-resistant prostate cancer (mCRPC), at Biotech Showcase 2026 in San Francisco, California on Monday, January 12, 2025 at 11:15 am PST at the Franciscan D (Ballroom Level). About PromiCell, Inc. PromiCell, is a clinical-stage cellular immunotherapy company with product candidates representing highly differentiated and novel CAR T and TCR T platforms to be developed across separate solid and hematologic types of cancer. Our pipeline of innovative products includes STEAP 1 CAR T cells, HA-1 T

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye